
Thanks for all the positive messages re FOCUS4C. Beyond delighted to see this in @guardian theguardian.com/society/2021…

Optimist. Prof GI medical oncology. Coffee, Irn-Bru & dog enthusiast @foxtrotstudy @focus4trial @ArielTrial #pelotonuk 🇪🇺

Thanks for all the positive messages re FOCUS4C. Beyond delighted to see this in @guardian theguardian.com/society/2021…

#ESMO26: Disappointing results with mFOLFIRINOX chemotherapy intensification in the phase III IROCAS #ClinicalTrial reinforces how much work remains to be done in high-risk, locally advanced #ColonCancer, as discussed by @JenSeligmann #InsightsbyESMO ➡️ ow.ly/L6Vf50ZZsB4

👏👏👏 FOxTROT 5 testing peri-op dostarlimab in MSI-H locally advanced colon cancer in older or frail patients. Thanks to our fantastic 🇬🇧 investigators. FOxTROT 6 to follow soon…. @yorkshirecancer @adbeggs @JenSeligmann @LTHTResearch

Jordan Appleyard Presents HER3 Analysis from FOxTROT Trial at ASCO GI - @JenSeligmann oncodaily.com/voices/jenny-s… #Cancer #ASCOGI26 #OncoDaily #Oncology #MedEd #MedTwitter #MedX #MedOnc @CancerWorldmag

🆕Article of the Month podcast🎧: @tompowles1 discusses the FOxTROT trial in locally advanced colon cancer with @JenSeligmann tinyurl.com/2sv3eyf4 For the full study report see: doi.org/10.1016/j.annonc.202…

#ESMO25 @myESMO A pleasure to join this symposium with @JenSeligmann & Julien Taieb ➡️ more choices in refractory mCRC ✅ ➡️ needs a tailored approach to optimize tx @TakedaOncology @myESMO #ESMOAmbassador

Neoadjuvant IO for locally advanced MSS colon ca…. This article helps us take a further step forward by demonstrating clear efficacy and signals towards biomarkers for pt selection. 💥💥huge congrats to my team neoadjuvant dear friend and team! We will get there in colon cancer
Very proud and happy to share that our work on neoadjuvant IO in pMMR colon cancers has been published online in @Nature after presentation @myESMO #ESMO25. Preview: rdcu.be/eLTN1 Read on how genomic instability, P53mt and proliferation may aid in predicting responses.

My take homes.... Further support of neoadjuvant IO esp for high risk pts Chemo no or limited role for dMMR early CC (?ATOMIC strategy) Clinical staging CAN identify high risk pts 20% recurrence relevant when effective rx available! @MyriamChalabi @CRUKresearch @oncodaily

Proud to present combined NICHE-2 & FOXTROT analysis in dMMR locally advanced CC -Neoadjuvant IO superior to chemo -20% relapses with chemo in "good prognosis" group; 30% if T4 -Minimal path response to chemo - Clinical staging identified high risk group

Thanks for highlighting!! @MyriamChalabi
NICHE-2 absolutely delivers. Game over for chemo in dMMR colon cancer 💥🧬 In locally advanced dMMR colon cancer, FOxTROT already showed us chemo doesn’t work, and now NICHE-2 makes it undeniable. 💊 Neoadjuvant nivolumab + ipilimumab → • 99% pathologic response • 67% pathologic CR • Zero recurrences to date at 3 years 🪦 This is the final coffin nail for perioperative chemotherapy in this setting. ATOMIC is already on life support despite being published less than a year ago. The real question now: with Cercek’s rectal data, can we safely omit surgery next? At minimum, this should be the new standard. At maximum, it’s the start of a paradigm shift. @OncoAlert @TheGutOncLab #ESMO25

Durvalumab & tremelimumab + local partial tumour ablation in pts with unresectable liver mts from mCRC: results of the EORTC-1560-GITCG ph II study (ILOC) in @ESMO_Open. No benefit with ICIs combination in this pts group with high therapeutic unmet need. esmoopen.com/article/S2059-7…

@adbeggs @FoxtrotStudy @chrisjmwilliams @OncoAlert @LIMRLeeds

🤔Pani had little effect on path response 👍Prospective trial in LACC RAS/RAF-wt EREG/AREG pts planned ❓Consider in LARC This will be my last tweet - hope to see you on Bluesky 👋 @b

🎆 Now online - my 2 fav topics in one paper 👍FOxTROT Ph2 FOLFOX+/- pani in locally advanced RAS/RAF-wt colon cancer 👍Convincing activity of anti-EGFR on long term outcomes, esp in hyperselected pts ❓Time to re-think targeted agents in LACC/LARC annalsofoncology.org/article…

Just finished. Very interesting #MiniOral #ESMOAsia24 session in #PDAC and #Biliary that I had the pleasure to co-chair (and discuss) with @JenSeligmann Posts coming with my thoughts 😉 Thanks @LorenzaRimassa for the 📸 🫶 @myESMO
The mini oral session on #GI cancer continues at #ESMOAsia24 in #Singapore. More abstracts on gastric, gastroesophageal, and GEJ cancer, but also on #BTC and #PDAC @myESMO @DrAngelaLamarca @JenSeligmann

Check out our editorial on high-risk stage II colon cancer: a call for clinicians to exercise caution when withdrawing oxaliplatin and when interpreting subanalyses sciencedirect.com/science/ar… @DrClaireGallois @JenSeligmann